N/A N=40 Escitalopram Treatment of Night Eating Syndrome
Night Eating Syndrome
Primary: Night Eating Questionnaire — -13.0; -10.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=87 Brain Imaging and Treatment Studies of the Night Eating Syndrome
Night Eating Syndrome
Primary: Change in Symptoms of NES — 46.1; 11.8; 17.4; NA percentage of calories after dinner
N/A N=845 MTNR1B SNP*Food Timing Interaction on Glucose Control
Non-Diabetic Disorder of Endocrine Pancreas
Primary: Area Under the Curve (AUC) Glucose — 278.84; 268.92; 260.66; 282.21 mg*h/dL
N/A N=20 Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern
Diet-induced Thermogenesis
Primary: Intra-individual Variation in Morning Diet-induced Thermogenesis (DIT) Evaluated by Calorimetric Exam After the Consumption of a Meal at 8:00 am Compared With Evening…
N/A N=36 Daytime vs. Delayed Eating Among Obese Individuals
Obesity
Primary: Body Mass (Weight) — -2.1067; -2.1887 kg
N/A N=22 Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity
Pediatric Obesity · Meal Timing
Primary: Change in Insulinogenic Index From Baseline After Test Meal From Venous Sample — 268; 215; 153 Microunits per milliliter
N/A N=17 Randomized Study of Daytime vs. Delayed Eating: Effect on Weight and Metabolism
Obesity
Primary: Body Mass Changes Between the Daytime vs. Delayed Eating Conditions — -1.1; 0.2 kg
Early Phase 1 N=34 Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder
Sleep-Related Eating Disorder
Primary: Change in Frequency of Sleep-related Eating Episodes (Time Frame: Comparing Final Study Visit to Baseline) — -41.2; -20.0 change in % of nights eating per week
N/A N=20 Binge Eating Syndrome Treatment for Older Women (BESTOW)
Binge Eating
Primary: Feasibility - Usage Rating Profile - Intervention — 5.44; 5.53 score on a scale
N/A N=6 Time Restricted Eating Pilot - Bariatrics
Time Restricted Feeding
Primary: Weight — -.07 kg
N/A N=81 Pilot Study of Time Restricted Feeding as a Weight Loss Intervention
Obesity
Primary: Changes in Body Weight — -5.1; -6.2 kg
N/A N=60 The Association Between Endometriosis, Obesity and nesfatin1
Endometriosis
Primary: Serum Nesfatin 1 — 190; 510 picogram/millilitre — p=0.05
N/A N=19 Eating Chocolate at the Right Time Benefits the Circadiam Sytem and Metabolic Efficiency.
Menopause
Primary: Resting Energy Expenditure (Indirect Calorimetry) — 1249.33; 1377.67; 1360.40; 1468.50 kcal/day
N/A N=25 Sleep Timing and Insulin Resistance in Adolescents With Obesity
Obesity
Primary: Dim Light Melatonin Onset and Offset — 21.33; 8.32 decimal hours
N/A N=12 Influence of Nocturnal Light Exposure on the Impairment of Glucose Tolerance Induced by Chronic Sleep Restriction
Glucose Intolerance · Sleep Deprivation · Sleep
Primary: Impairment of Insulin Sensitivity — -0.80; 0.55 (mU/L)^-1 min^-1
Phase 2 N=10 Neurobiology of Bulimia Nervosa
Bulimia Nervosa
Primary: Change in Binge Eating Sum Score — -0.60; 0.89 score on a scale
N/A N=30 Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents
Obesity
Primary: Peak Growth Hormone (GH) on the GH Stimulation Test — 40.1; 25.2 ng/ml — p=<0.05
Phase 4 N=88 Monoamine Contributions to Neurocircuitry in Eating Disorders
Eating Disorder
Primary: 5-HT Transporter Binding as Measured During the PET Scan — 1.68; 1.54; 1.46; 1.60 binding potential (BPND) — p=> 0.05
Phase 2 N=39 Melatonin and the Metabolic Syndrome
Metabolic Syndrome
Primary: Metabolic Syndrome Components — -2.7; 4.7 mmHg — p=0.013
N/A N=33 Time Restricted Eating for Metabolic and Psychological Optimization
Mild Cognitive Impairment · Obesity
Primary: Change in Memory Composite Rank — 6.22 rank — p=<0.001
N/A N=176 Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence
Eveningness/Sleep
Primary: Total Sleep Time (TST) Average on Weeknights Via Daily Sleep Diary — 24.72; 13.02 Minutes — p=0.34
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
N/A N=44 P20 Extending Sleep to Reverse Metabolic Syndrome
Metabolic Syndrome
Primary: SASI Acceptability Questionnaire Score at Pre-Intervention — 3.91 score on a scale
Early Phase 1 N=13 Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia Nervosa
Primary: Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI)…
N/A N=100 Self-Control in Bulimia Nervosa
Bulimia Nervosa
Primary: Brain Activation Associated With P(Stop) — 0.02; 0.11; 0.04; 0.05 BOLD Signal
N/A N=10 Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
N/A N=50 Time Limited Eating in Adolescents (Time LEAd): a Pilot Study
Obesity, Childhood
Primary: Percent Change in BMI in Excess of the 95th Percentile (%BMIp95) — -3.27; -3.76; -4.85 percent — p=0.4
Phase 2 N=38 Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome
Hyperphagia in Prader-Willi Syndrome
Primary: Change From Baseline in Hyperphagia in Prader-Willi Syndrome (PWS) Questionnaires- Responsiveness (HPWSQ-R) Total Score at End-of-treatment (Day 15) — -15.6; -8.9 score…
Phase 3 N=528 Dasotraline Binge Eating Disorder Extension Study
Binge Eating Disorder
Primary: Frequency and Severity of Suicidal Ideation Using the Columbia-suicide Severity Rating Scale (C-SSRS) — 515; 7; 3; 1 Participants
N/A N=399 Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants